NCT06353191

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Detailed description

PRIMARY OBJECTIVE: I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study.

Conditions

• Hematopoietic and Lymphatic System Neoplasm
• Malignant Solid Neoplasm

Interventions

Type	Name	Description
OTHER	Non-Interventional Study	Non-interventional study

Timeline

• Start date: 2019-05-03
• Primary completion: 2031-12-31
• Completion: 2031-12-31
• First posted: 2024-04-08
• Last updated: 2026-02-27

Locations

4 sites across 1 country: United States